不同剂量重组人干扰素α2b联合阿奇霉素治疗小儿急性支气管炎的疗效比较研究

A Comparative Study of Different Doses of Recombinant Human Interferonα2b Combined with Azithromycin in the Treatment of Children with Acute Bronchial Pneumonia

目的:探讨不同剂量重组人干扰素α2b联合阿奇霉素治疗小儿急性支气管炎的疗效差异。方法:选取2018年10月~2020年9月本院收治的100例急性支气管炎患儿,根据治疗方案分为A组(n=39)、B组(n=31)和C组(n=30)。A组采用常规治疗和阿奇霉素10 mg/(kg·d)静脉滴注治疗7天;B组在A组治疗的基础上雾化吸入重组人干扰素α2b注射液10万U/kg/次,qd,持续治疗7天;C组在A组治疗的基础上雾化吸入重组人干扰素α2b注射液20万U/kg/次,qd,持续治疗7天,评价比较3组疗效。检测比较治疗前后3组白细胞(WBC)和淋巴细胞所占百分比水平。统计比较3组住院时间、临床症状消失时间以及不良反应发生率。结果:A组治疗有效率低于B和C组,发热、咳嗽、喘憋、肺部啰音等临床症状消失时间长于B和C组(P<0.05)。3组治疗后的WBC和淋巴细胞所占百分比均较其治疗前降低,且A组治疗后的WBC和淋巴细胞所占百分比水平高于B和C组(P<0.05)。但B组和C组治疗有效率、治疗前后WBC和淋巴细胞所占百分比水平、临床症状消失时间比较无统计学差异(P>0.05)。3组住院时间比较无统计学差异(P>0.05)。A和B组总不良反应发生率、胃肠道不良反应发生率比较无统计学差异(P>0.05);但C组总不良反应发生率、胃肠道不良反应发生率高于A和B组(P<0.05)。结论:重组人干扰素α2b联合阿奇霉素治疗小儿急性支气管炎有助于改善炎症和疗效,其中以10万U/kg/次,qd的重组人干扰素α2b联合阿奇霉素治疗安全性更佳。

Objective:To investigate the difference in the efficacy rate of different doses of recombinant human interferonα2b combined with azithromycin in the treatment of children with acute bronchial pneumonia.Methods:100 children with acute bronchial pneumonia admitted from October 2018 to September 2020 were selected.According to their treatment plan,the children were divided into group A(n=39),group B(n=31)and group C(n=30).Group A was treated with conventional treatment and intravenous infusion of azithromycin 10 mg/(kg·d)for 7 days.In group B,on the basis of the treatment of group A,the children had aerosol inhalation of recombinant human interferonα2b injection with 100000 U/kg/time,qd,continuous treatment for 7 days.In group C,on the basis of the treatment of group A,the children had aerosol inhalation of recombinant human interferonα2b injection with 200000 U/kg/time,qd,continuous treatment for 7 days.The efficacy of the three groups were evaluated and compared.The white blood cells(WBC)and percentage levels of lymphocytes in the three groups before and after treatment were detected and compared.Hospitalization time,clinical symptoms disappeared time,and the incidence of other adverse reactions rates in the three groups were statistically compared.Results:The effective rate of treatment in group A was lower than those in group B and C,and the disappearance time of clinical symptoms such as fever,cough,wheezing,and pulmonary rales in group A were longer than that in group B and C(P<0.05).The percentages of WBC and lymphocytes in the three groups after treatment were all lower than those before treatment,and the after treatment percentage levels of WBC and lymphocytes in group A were higher than those in group B and C(P<0.05).However,there was no significant difference in the effective rate of treatment,the percentages of WBC and lymphocytes before and after treatment,and the disappearance time of clinical symptoms between group B and C(P>0.05).There was no significant difference in the length of hospital stay in the three groups(P>0.05).There was no significant difference in the incidence of total adverse and gastrointestinal adverse reactions in group A and B(P>0.05);however,the incidence of total adverse and gastrointestinal adverse reactions in group C was higher than those in group A and B(P<0.05);and there was no significant difference in the incidence rate of other adverse reactions among the three groups(P>0.05).Conclusion:Recombinant human interferonα2b combined with azithromycin in the treatment of children with acute bronchial pneumonia is helpful to improve inflammation and curative effect.Among them,100000 U/kg/time,qd of recombinant human interferonα2b combined with azithromycin treatment is safer.